Biotechnology firm Gate2Brain, a CataloniaBio & HealthTech member, has won the Barcelona Activa pre-acceleration contest for early stage high-impact entrepreneurial projects.
The programme will allow Gate2Brain to validate its business model with experts, share experiences with similar projects, accelerate access to market and get a €5,000 prize.
Gate2Brain was created in 2020 as a spin-off of the University of Barcelona, IRB Barcelona and Sant Joan de Déu Research Institute. The company has developed a peptide-based technology platform for developing therapies that cross the blood-brain barrier.
Its R&D pipeline includes a first-in-class drug (G2B-001) that has been shown to be effective in preclinical studies with paediatric cancers (high-grade gliomas, DIPG, Ewing sarcoma, Rhabdomyosarcoma and Neuroblastoma).
Photo: Meritxell Teixidó, co-founder and CEO of Gate2Brain at the awards ceremony.
Want to learn more about what Gate2Brain does? We recommend this video of CataloniaBio & HealthTech:
Comments